sed on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our divestiture of non-strategic assets, our restructuring
initiatives, our operational strategy, our financial performance and our
growth strategy. If our underlying assumptions turn out to be incorrect, or
if certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by
our forward-looking statements. These factors, in some cases, have affected
and in the future (together with other factors) could affect our ability to
implement our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business decisions
made by us and our competitors. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A-
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A
- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward- looking statements to reflect any change in our
expectations or in events, conditions
'/>"/>
SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program2.
Boston Scientific Announces Results for Third Quarter Ended September 30, 20073.
Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA4.
The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-65.
Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator6.
Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board7.
Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results8.
New Scientists Boost Disease-based Research at Boston Biomedical Research Institute9.
Genzyme Begins Major Expansion of Boston Manufacturing Facility10.
Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System11.
Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University